Baseline patient, disease, and transplant characteristics stratified by donor source and PTCy
| Variable . | HaploCy, N (%), N = 757 . | SibCy, N (%), N = 403 . | SibCNI, N (%), N = 1605 . | P . |
|---|---|---|---|---|
| Patient related | ||||
| No. of centers | 100 | 77 | 100 | |
| Sex, male | 459 (61) | 243 (60) | 933 (58) | .450 |
| Age, median (range), y | 58 (3-78) | 46 (3-75) | 57 (2-78) | <.001 |
| Age at transplant, y | <.001 | |||
| ≤20 | 86 (11) | 27 (7) | 126 (8) | |
| 21-40 | 112 (15) | 131 (33) | 252 (16) | |
| 41-60 | 223 (29) | 149 (37) | 597 (37) | |
| >60 | 336 (44) | 96 (24) | 630 (39) | |
| Karnofsky/Lansky performance at HCT | <.001 | |||
| <80 | 119 (16) | 65 (16) | 200 (12) | |
| 80-89 | 229 (30) | 102 (25) | 449 (28) | |
| ≥90 | 390 (52) | 233 (58) | 946 (59) | |
| Missing | 19 (3) | 3 (<1) | 10 (<1) | |
| Race/ethnicity | <.001 | |||
| White | 444 (59) | 239 (59) | 1109 (69) | |
| African American | 131 (17) | 56 (14) | 107 (7) | |
| Asian/Pacific Islander, non-Hispanic | 54 (7) | 30 (7) | 106 (7) | |
| Native American, non-Hispanic | 3 (<1) | 1 (<1) | 9 (<1) | |
| Hispanic | 77 (10) | 49 (12) | 145 (9) | |
| Missing | 48 (6) | 28 (7) | 127 (8) | |
| Donor related | ||||
| Donor age, median(range), y | 36 (9-76) | 45 (4-72) | 54 (2-82) | <.001 |
| Donor age (in decades) | <.001 | |||
| 0-20 | 52 (7) | 37 (9) | 125 (8) | |
| 21-40 | 414 (55) | 131 (33) | 279 (17) | |
| 41-60 | 253 (33) | 172 (43) | 698 (43) | |
| >60 | 32 (4) | 63 (16) | 487 (30) | |
| Missing | 6 (<1) | 0 | 16 (<1) | |
| Donor/recipient sex match | .001 | |||
| Male-male | 289 (38) | 156 (39) | 507 (32) | |
| Male-female | 180 (24) | 99 (25) | 347 (22) | |
| Female-male | 170 (22) | 87 (22) | 426 (27) | |
| Female-female | 118 (16) | 61 (15) | 324 (20) | |
| Missing | 0 | 0 | 1 (<1) | |
| Donor/recipient CMV status | .04 | |||
| +/+ | 326 (43) | 172 (43) | 684 (43) | |
| +/− | 54 (7) | 36 (9) | 163 (10) | |
| −/+ | 217 (29) | 101 (25) | 383 (24) | |
| −/− | 131 (17) | 79 (20) | 327 (20) | |
| Recipient missing | 3 (<1) | 2 (<1) | 15 (<1) | |
| Donor missing | 26 (3) | 13 (3) | 33 (2) | |
| Disease related | ||||
| Disease | <.001 | |||
| AML | 528 (70) | 310 (77) | 1025 (64) | |
| ALL | 26 (3) | 19 (5) | 60 (4) | |
| MDS | 203 (27) | 74 (18) | 520 (32) | |
| HCT-CI | .817 | |||
| 0 | 199 (26) | 103 (26) | 392 (24) | |
| 1-2 | 209 (28) | 124 (31) | 447 (28) | |
| 3-4 | 211 (28) | 104 (26) | 476 (30) | |
| 5+ | 137 (18) | 71 (18) | 285 (18) | |
| Missing | 1 (<1) | 1 (<1) | 5 (<1) | |
| Disease status | <.001 | |||
| AML/ALL, early | 308 (41) | 189 (47) | 719 (45) | |
| AML/ALL, intermediate | 143 (19) | 77 (19) | 210 (13) | |
| AML/ALL, advanced | 97 (13) | 61 (15) | 144 (9) | |
| AML/ALL, unknown | 6 (<1) | 2 (<1) | 15 (<1) | |
| MDS, early | 76 (10) | 24 (6) | 179 (11) | |
| MDS, advanced | 127 (17) | 50 (12) | 338 (21) | |
| Cytogenetics for AML/ALL (n = 1968) | .22 | |||
| Favorable | 23 (3) | 18 (4) | 39 (2) | |
| Intermediate (including normal) | 298 (39) | 168 (42) | 601 (37) | |
| Poor | 203 (27) | 132 (33) | 374 (23) | |
| Other | 20 (3) | 6 (1) | 49 (3) | |
| Not tested/missing | 10 (1) | 5 (1) | 22 (1) | |
| IPSS-R before transplant; MDS only (n = 797) | .30 | |||
| Very low/low | 86 (11) | 36 (9) | 193 (12) | |
| Intermediate | 53 (7) | 22 (5) | 160 (10) | |
| High/very high | 43 (6) | 13 (3) | 111 (7) | |
| Missing | 21 (3) | 3 (<1) | 56 (3) | |
| Transplant related | ||||
| Graft type | <.001 | |||
| Bone marrow | 308 (41) | 131 (33) | 200 (12) | |
| Peripheral blood | 449 (59) | 272 (67) | 1405 (88) | |
| Conditioning regimen intensity | <.001 | |||
| Myeloablative | 314 (41) | 222 (55) | 935 (58) | |
| RIC/NMA | 443 (59) | 181 (45) | 670 (42) | |
| GVHD prophylaxis | ||||
| Cyclophosphamide | 757 | 403 | — | |
| TAC/CSA + MMF + others | — | — | 362 (23) | |
| TAC/CSA + MTX + others | — | — | 1243 (77) | |
| TBI, yes | 531 (70) | 234 (58) | 436 (27) | <.001 |
| G-CSF, GM-CSF planned | <.001 | |||
| No | 133 (18) | 84 (21) | 1223 (76) | |
| Yes | 620 (82) | 319 (79) | 379 (24) | |
| Missing | 4 (<1) | 0 | 3 (<1) | |
| Time from diagnosis to transplant, median (range), mo | 7 (1-165) | 7 (<1-396) | 5 (1-556) | <.001 |
| Time from diagnosis to transplant | <.001 | |||
| <6 mo | 315 (42) | 180 (45) | 890 (55) | |
| 6 mo to 1 y | 195 (26) | 117 (29) | 348 (22) | |
| >1 y | 246 (32) | 105 (26) | 363 (23) | |
| Missing | 1 (<1) | 1 (<1) | 4 (<1) | |
| Year of transplant | <.001 | |||
| 2012-2014 | 170 (22) | 87 (22) | 806 (50) | |
| 2015-2017 | 587 (78) | 316 (78) | 799 (50) | |
| Median follow-up of survivors, mo | 25 (3-74) | 25 (3-69) | 37 (2-75) |
| Variable . | HaploCy, N (%), N = 757 . | SibCy, N (%), N = 403 . | SibCNI, N (%), N = 1605 . | P . |
|---|---|---|---|---|
| Patient related | ||||
| No. of centers | 100 | 77 | 100 | |
| Sex, male | 459 (61) | 243 (60) | 933 (58) | .450 |
| Age, median (range), y | 58 (3-78) | 46 (3-75) | 57 (2-78) | <.001 |
| Age at transplant, y | <.001 | |||
| ≤20 | 86 (11) | 27 (7) | 126 (8) | |
| 21-40 | 112 (15) | 131 (33) | 252 (16) | |
| 41-60 | 223 (29) | 149 (37) | 597 (37) | |
| >60 | 336 (44) | 96 (24) | 630 (39) | |
| Karnofsky/Lansky performance at HCT | <.001 | |||
| <80 | 119 (16) | 65 (16) | 200 (12) | |
| 80-89 | 229 (30) | 102 (25) | 449 (28) | |
| ≥90 | 390 (52) | 233 (58) | 946 (59) | |
| Missing | 19 (3) | 3 (<1) | 10 (<1) | |
| Race/ethnicity | <.001 | |||
| White | 444 (59) | 239 (59) | 1109 (69) | |
| African American | 131 (17) | 56 (14) | 107 (7) | |
| Asian/Pacific Islander, non-Hispanic | 54 (7) | 30 (7) | 106 (7) | |
| Native American, non-Hispanic | 3 (<1) | 1 (<1) | 9 (<1) | |
| Hispanic | 77 (10) | 49 (12) | 145 (9) | |
| Missing | 48 (6) | 28 (7) | 127 (8) | |
| Donor related | ||||
| Donor age, median(range), y | 36 (9-76) | 45 (4-72) | 54 (2-82) | <.001 |
| Donor age (in decades) | <.001 | |||
| 0-20 | 52 (7) | 37 (9) | 125 (8) | |
| 21-40 | 414 (55) | 131 (33) | 279 (17) | |
| 41-60 | 253 (33) | 172 (43) | 698 (43) | |
| >60 | 32 (4) | 63 (16) | 487 (30) | |
| Missing | 6 (<1) | 0 | 16 (<1) | |
| Donor/recipient sex match | .001 | |||
| Male-male | 289 (38) | 156 (39) | 507 (32) | |
| Male-female | 180 (24) | 99 (25) | 347 (22) | |
| Female-male | 170 (22) | 87 (22) | 426 (27) | |
| Female-female | 118 (16) | 61 (15) | 324 (20) | |
| Missing | 0 | 0 | 1 (<1) | |
| Donor/recipient CMV status | .04 | |||
| +/+ | 326 (43) | 172 (43) | 684 (43) | |
| +/− | 54 (7) | 36 (9) | 163 (10) | |
| −/+ | 217 (29) | 101 (25) | 383 (24) | |
| −/− | 131 (17) | 79 (20) | 327 (20) | |
| Recipient missing | 3 (<1) | 2 (<1) | 15 (<1) | |
| Donor missing | 26 (3) | 13 (3) | 33 (2) | |
| Disease related | ||||
| Disease | <.001 | |||
| AML | 528 (70) | 310 (77) | 1025 (64) | |
| ALL | 26 (3) | 19 (5) | 60 (4) | |
| MDS | 203 (27) | 74 (18) | 520 (32) | |
| HCT-CI | .817 | |||
| 0 | 199 (26) | 103 (26) | 392 (24) | |
| 1-2 | 209 (28) | 124 (31) | 447 (28) | |
| 3-4 | 211 (28) | 104 (26) | 476 (30) | |
| 5+ | 137 (18) | 71 (18) | 285 (18) | |
| Missing | 1 (<1) | 1 (<1) | 5 (<1) | |
| Disease status | <.001 | |||
| AML/ALL, early | 308 (41) | 189 (47) | 719 (45) | |
| AML/ALL, intermediate | 143 (19) | 77 (19) | 210 (13) | |
| AML/ALL, advanced | 97 (13) | 61 (15) | 144 (9) | |
| AML/ALL, unknown | 6 (<1) | 2 (<1) | 15 (<1) | |
| MDS, early | 76 (10) | 24 (6) | 179 (11) | |
| MDS, advanced | 127 (17) | 50 (12) | 338 (21) | |
| Cytogenetics for AML/ALL (n = 1968) | .22 | |||
| Favorable | 23 (3) | 18 (4) | 39 (2) | |
| Intermediate (including normal) | 298 (39) | 168 (42) | 601 (37) | |
| Poor | 203 (27) | 132 (33) | 374 (23) | |
| Other | 20 (3) | 6 (1) | 49 (3) | |
| Not tested/missing | 10 (1) | 5 (1) | 22 (1) | |
| IPSS-R before transplant; MDS only (n = 797) | .30 | |||
| Very low/low | 86 (11) | 36 (9) | 193 (12) | |
| Intermediate | 53 (7) | 22 (5) | 160 (10) | |
| High/very high | 43 (6) | 13 (3) | 111 (7) | |
| Missing | 21 (3) | 3 (<1) | 56 (3) | |
| Transplant related | ||||
| Graft type | <.001 | |||
| Bone marrow | 308 (41) | 131 (33) | 200 (12) | |
| Peripheral blood | 449 (59) | 272 (67) | 1405 (88) | |
| Conditioning regimen intensity | <.001 | |||
| Myeloablative | 314 (41) | 222 (55) | 935 (58) | |
| RIC/NMA | 443 (59) | 181 (45) | 670 (42) | |
| GVHD prophylaxis | ||||
| Cyclophosphamide | 757 | 403 | — | |
| TAC/CSA + MMF + others | — | — | 362 (23) | |
| TAC/CSA + MTX + others | — | — | 1243 (77) | |
| TBI, yes | 531 (70) | 234 (58) | 436 (27) | <.001 |
| G-CSF, GM-CSF planned | <.001 | |||
| No | 133 (18) | 84 (21) | 1223 (76) | |
| Yes | 620 (82) | 319 (79) | 379 (24) | |
| Missing | 4 (<1) | 0 | 3 (<1) | |
| Time from diagnosis to transplant, median (range), mo | 7 (1-165) | 7 (<1-396) | 5 (1-556) | <.001 |
| Time from diagnosis to transplant | <.001 | |||
| <6 mo | 315 (42) | 180 (45) | 890 (55) | |
| 6 mo to 1 y | 195 (26) | 117 (29) | 348 (22) | |
| >1 y | 246 (32) | 105 (26) | 363 (23) | |
| Missing | 1 (<1) | 1 (<1) | 4 (<1) | |
| Year of transplant | <.001 | |||
| 2012-2014 | 170 (22) | 87 (22) | 806 (50) | |
| 2015-2017 | 587 (78) | 316 (78) | 799 (50) | |
| Median follow-up of survivors, mo | 25 (3-74) | 25 (3-69) | 37 (2-75) |
CSA, cyclosporine; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage-colony stimulating factor; IPSS-R, Revised-International Prognostic Scoring System; MMF, mycophenolate mofetil; MTX, methotrexate; TAC, tacrolimus.